Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43866   clinical trials with a EudraCT protocol, of which   7287   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-001884-21
    Sponsor's Protocol Code Number:VTI-210
    National Competent Authority:Austria - BASG
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2015-05-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedAustria - BASG
    A.2EudraCT number2013-001884-21
    A.3Full title of the trial
    A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (sAAH) AND LILLE SCORE FAILURE
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study examines the safety and efficacy of ELAD treatment as a continuous liver support to a subject with compromised liver function owing to severe acute alcoholic hepatitis who is a Lille score failure (Lille score >0.45), allowing time for the subject's native liver to regenerate to a functional state. The primary objective is to evaluate safety and efficacy with respect to overall survival of subjects through study termination (after last surviving enrolled subject completes Study Day 91).
    A.4.1Sponsor's protocol code numberVTI-210
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01829347
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorVITAL THERAPIES, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportVITAL THERAPIES, INC.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAndrea Loewen-Rodriguez, Vital Therapies Inc.
    B.5.2Functional name of contact pointVP, Regulatory Affairs and QA
    B.5.3 Address:
    B.5.3.1Street Address15010 Avenue of Sciences, Suite 200
    B.5.3.2Town/ citySan Diego
    B.5.3.3Post codeCA 92128
    B.5.3.4CountryUnited States
    B.5.4Telephone number001858673 6840
    B.5.5Fax number001858673 6843
    B.5.6E-mailaloewen@vitaltherapies.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1143
    D.3 Description of the IMP
    D.3.1Product nameELAD
    D.3.2Product code ELAD System
    D.3.4Pharmaceutical form Living tissue equivalent
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPHaemodialysis
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman C3A hepatoblastoma cells
    D.3.9.3Other descriptive nameELAD Human Cell-Based Bio-Artificial Liver Support System
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product Yes
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Yes
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberELAD falls within the definition of somatic cell therapy medicinal product and can further be considered a combined ATMP. EMA/CAT/345680/2010 & EMA/463750/2010
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe Acute Alcoholic Hepatitis (sAAH)
    E.1.1.1Medical condition in easily understood language
    Severe Acute Alcoholic Hepatitis (sAAH)
    E.1.1.2Therapeutic area Body processes [G] - Metabolic Phenomena [G03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10019755
    E.1.2Term Hepatitis chronic active
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) in subjects with a clinical diagnosis of severe acute alcoholic hepatitis (sAAH) who are Lille score failures (Lille score >0.45). Follow-up Protocol VTI 210E will provide additional survival data up to a maximum of 5 years that will be included, as available, through VTI-210 study termination (after all enrolled subjects complete Study Day 91, are lost to follow up or withdraw consent, or die before that Study Day). This will be assessed using a Kaplan-Meier survival analysis of the intent-to-treat (ITT) population utilizing a log-rank test to evaluate the null hypothesis of equality of survival curves. The randomization and the analysis model will be stratified by whether or not the clinical diagnosis of sAAH was confirmed with a liver biopsy.
    E.2.2Secondary objectives of the trial
    Secondary objectives are to evaluate the proportion of survivors (ITT population) at Study Days 28 and 91 using a chi-square test.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet ALL inclusion criteria to be eligible for the study:

    1. Age ≥ 18 years;

    2. Total bilirubin ≥ 8 mg/dL;

    3. Medical history of alcohol abuse with evidence of a causal and temporal (<6 weeks) relationship to the use of alcohol and hospital admission for this episode of sAAH;

    4. Maddrey score of ≥ 32;

    5. A clinical diagnosis of severe acute alcoholic hepatitis (sAAH) defined as meeting two or more of the following:

    a. Hepatomegaly,
    b. AST > ALT,
    c. Ascites,
    d. Leukocytosis (WBC count above lab normal at site)

    6. Subject must have either:

    a. A liver biopsy that, in the Investigator's opinion, confirms a diagnosis of sAAH (stratum A);
    OR
    b. In the Investigator's opinion, a liver biopsy is not justified due to the risk versus the diagnostic value, and no confirmatory liver biopsy is available, in which case the clinical diagnosis is sufficient (stratum B);

    7. Subject must be a Lille score failure(Lille score > 0.45) as defined in this study;

    8. Subject must be eligible for Standard of Care treatment as defined in protocol;

    9. Subject or legally authorized representative must provide Informed Consent for all phases of the study (Treatment and 5-year Follow-Up Registry).
    E.4Principal exclusion criteria
    Subjects must NOT have any of the following exclusion criteria:

    1. Platelet count < 50,000/mm3;

    2. International Normalization Ratio (INR) > 3.0;

    3. MELD Score > 35;

    4. Evidence of infection unresponsive to antibiotics (e.g. increased tissue involvement relative to initial diagnosis, clinical worsening of symptom, etc.) indicated by any of the following:

    a. Presence of sepsis or septic shock; OR
    b. Positive blood cultures (Bacteremia, Fungemia) within 72 hours prior to Randomization; OR
    c. Presence of spontaneous bacterial peritonitis during the 2 days prior to Randomization
    d. Clinical and radiological signs of pneumonia;

    5. Evidence of jaundice for >3 months;

    6. Hospital admission for any other episodes of liver decompensation not related to sAAH (other than this episode of sAAH) within the past 2 months;

    7. Evidence of hemodynamic instability as defined by the following:
    a. Systolic blood pressure < 90 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low-dose pressor support; OR
    b. Mean arterial pressure (MAP) < 60 mmHg with evidence of diminished perfusion unresponsive to fluid resuscitation and/or low dose pressor support; OR
    c. Requirement for escalating doses of vasopressor support prior to Screening; OR
    d. Subject at maximum vasopressor dose at Screening or Randomization (low doses are allowed); low dose vasopressor doses are defined as:
    Dobutamine: Low doses: 2.5 to 5.0 μg/kg/min
    Dopamine: Low doses: 0.5 to 2 μg/kg/min
    Norepinephrine: Low doses: 0.01 to 0.02 μg/kg/min
    Phenylephrine: Low doses: 0.05 to 1 μg/kg/min
    Vasopressin: Low doses: 0.01 to 0.02 U/min

    8. Either clinical evidence of active bleeding, or of a major haemorrhage. Major haemorrhage is defined as requiring ≥ 2 units packed red blood cells to maintain a stable haemoglobin occurring within 48 hours of Screening;

    9. Evidence of occlusive portal vein thrombosis impairing hepatopetal flow, or evidence of bile duct obstruction;

    10. Evidence by physical exam, history, or laboratory evaluation of significant concomitant disease with expected life expectancy of less than 3 months, including but not limited to:
    a. Severe acute or chronic cardiovascular, central nervous system, or pulmonary disease;
    b. Cancer that has metastasized or has not yet been treated;

    11. Clinical evidence of liver size reduction due to cirrhosis [liver size of the craniocaudal diameter (sagittal view) < 10 cm when measured on the mid-clavicular line (or equivalent measurement) by ultrasound, CT or MRI or liver volume < 750 cc as determined by CT or MRI], unless Investigator interpretation of the clinical evidence indicates liver size of < 10 cm or volume < 750 cc is not considered reduced for the individual subject;

    12. Chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks (not classified as hepatorenal syndrome);

    13. Uncontrolled seizures;

    14. Positive serologies for viral hepatitis B (HBsAg) or hepatitis C indicating acute/chronic infection or a positive viral load for either hepatitis B or C;

    15. Pregnancy as determined by β-human chorionic gonadotropin (HCG) results;

    16. Participation in another investigational drug, biologic, or device study within one month of enrolment, except for observational studies (the observational study setting should not affect the safety and/or efficacy of the VTI-210 clinical trial);

    17. Currently listed or scheduled for liver transplant during the 90-day study period;

    18. Previous liver transplant;

    19. Previous participation in a clinical trial involving ELAD as either ELAD or Control subject;

    20. Has a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or local equivalent) or any other Advanced Directive limiting Standard of Care in place (the DNR/DNI criterion is not applicable in the UK);

    21. Refusal to participate in the VTI-210E follow-up study;

    22. Is unable to provide an address for follow-up home visits.
    E.5 End points
    E.5.1Primary end point(s)
    Overall survival (OS) will be assessed using a Kaplan-Meier survival analysis of the ITT population utilizing a log-rank test to evaluate the null hypothesis of equality of survival curves, with follow-up Protocol VTI 210E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-210 study termination (after all enrolled subjects either complete Study Day 91, are lost to
    follow up or withdraw consent, or die before that Study Day). The model will be stratified by whether or not the clinical diagnosis of sAAH was confirmed with a liver biopsy. Model-based estimates and confidence limits will be calculated for median survival by treatment group and hazard rates along with the hazard ratio and its confidence limits. This analysis will also be carried out on the per-protocol (PP) population as a sensitivity analysis. In addition, a similar sensitivity analysis for Overall Survival will be carried out using only survival data captured up to the End of Study Day 91. Two-tailed alpha for the log-rank test will be set at 0.05. The statistical analysis plan will outline the methods used to define the ITT and PP populations and to account for missing data in this and all other analyses.
    E.5.1.1Timepoint(s) of evaluation of this end point
    After all enrolled subjects either complete Study Day 91, are lost to follow up or withdraw consent, or die before that Study Day.
    E.5.2Secondary end point(s)
    A chi-square test will be used to evaluate the proportion of subjects who survived at End of Study Day 28 and End of Study Day 91 based on the ITT population. These analyses will also be performed using a Cochran-Mantel-Haenszel (CMH) test stratified by whether or not the clinical diagnosis of sAAH was confirmed with a liver biopsy to compare the proportion of subjects who have survived at End of Study Day 28 and End of Study Day 91 respectively.
    CMH analyses are considered sensitivity analyses to help evaluate consistency across subgroups based on the stratification factor. Two tailed alpha will be set at 0.05 for each test.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary objectives are to evaluate the proportion of survivors at Study Days 28 and 91.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Standard of care treatment for sAAH (as defined in the protocol)
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Germany
    Ireland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 135
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 15
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Due to the critical nature of the subject's condition, they may not be able to understand or execute the informed consent at the time of screening.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 90
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    In addition, an extension of this study, VTI-210E, will provide extended follow-up of subjects enrolled in VTI-210 over a period of 5 years to determine incidence of survival, cancer, liver transplant and quality of life.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation National Institute for Health Research, Clinical Research Network
    G.4.3.4Network Country United Kingdom
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-08-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-05-19
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2015-08-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 30 04:20:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA